Alessio Schirone

1.3k total citations
22 papers, 432 citations indexed

About

Alessio Schirone is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alessio Schirone has authored 22 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alessio Schirone's work include HER2/EGFR in Cancer Research (10 papers), Breast Cancer Treatment Studies (7 papers) and Advanced Breast Cancer Therapies (5 papers). Alessio Schirone is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Breast Cancer Treatment Studies (7 papers) and Advanced Breast Cancer Therapies (5 papers). Alessio Schirone collaborates with scholars based in Italy, United States and Switzerland. Alessio Schirone's co-authors include Andrea Rocca, Sara Bravaccini, Dino Amadori, Alberto Farolfi, Roberta Maltoni, Daniele Andreis, Lorenzo Cecconetto, Anna Fedeli, Elisabetta Pietri and Patrizia Serra and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Alessio Schirone

21 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alessio Schirone Italy 12 242 173 144 124 52 22 432
Kateřina Bouchalová Czechia 12 229 0.9× 62 0.4× 128 0.9× 193 1.6× 32 0.6× 35 486
Sheau Wen Lok Australia 8 244 1.0× 82 0.5× 144 1.0× 179 1.4× 74 1.4× 25 431
Qiufan Zheng China 11 189 0.8× 139 0.8× 111 0.8× 153 1.2× 27 0.5× 38 353
Djamila Ouaret France 10 281 1.2× 142 0.8× 147 1.0× 278 2.2× 21 0.4× 15 583
LA Carey United States 12 439 1.8× 146 0.8× 307 2.1× 117 0.9× 45 0.9× 49 560
Salo Ooft Netherlands 4 386 1.6× 83 0.5× 186 1.3× 201 1.6× 25 0.5× 5 605
Jutta Groos Germany 6 292 1.2× 146 0.8× 125 0.9× 101 0.8× 25 0.5× 7 384
Erica Stringer-Reasor United States 16 388 1.6× 231 1.3× 268 1.9× 282 2.3× 83 1.6× 48 738
Xinghua Han China 15 224 0.9× 168 1.0× 289 2.0× 349 2.8× 21 0.4× 54 676
Sean E. Sissons United States 8 201 0.8× 75 0.4× 145 1.0× 242 2.0× 28 0.5× 11 476

Countries citing papers authored by Alessio Schirone

Since Specialization
Citations

This map shows the geographic impact of Alessio Schirone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessio Schirone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessio Schirone more than expected).

Fields of papers citing papers by Alessio Schirone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessio Schirone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessio Schirone. The network helps show where Alessio Schirone may publish in the future.

Co-authorship network of co-authors of Alessio Schirone

This figure shows the co-authorship network connecting the top 25 collaborators of Alessio Schirone. A scholar is included among the top collaborators of Alessio Schirone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessio Schirone. Alessio Schirone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fortini, Francesca, Francesco Vieceli Dalla Sega, Edoardo Lazzarini, et al.. (2024). ErbB2 ‐ NOTCH1 axis controls autophagy in cardiac cells. BioFactors. 51(1). e2091–e2091. 3 indexed citations
2.
Sanz, Juana María, Alessio Schirone, Antonio Frassoldati, et al.. (2024). miRNAs profile as a signature for cardiovascular disease in long-term breast cancer female survivors: a pilot study. European Heart Journal. 45(Supplement_1).
3.
Conté, Pierfranco, Giancarlo Bisagni, Federico Piacentini, et al.. (2023). Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.. Journal of Clinical Oncology. 41(17_suppl). LBA637–LBA637. 2 indexed citations
4.
5.
Caputo, Roberta, Marina Elena Cazzaniga, Andrea Sbrana, et al.. (2020). Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. BMC Cancer. 20(1). 232–232. 7 indexed citations
6.
Lupini, Laura, Cristian Bassi, Alessio Schirone, et al.. (2018). High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. Scientific Reports. 8(1). 4371–4371. 16 indexed citations
7.
Pietri, Elisabetta, Ilaria Massa, Sara Bravaccini, et al.. (2018). Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. The Oncologist. 24(6). 743–e205. 8 indexed citations
8.
9.
Rocca, Andrea, Lorenzo Cecconetto, Alessandro Passardi, et al.. (2017). Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology. 79(5). 863–871. 15 indexed citations
10.
Maltoni, Roberta, Valentina Casadio, Sara Ravaioli, et al.. (2017). Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer. Oncotarget. 8(10). 16642–16649. 27 indexed citations
11.
Bronte, Giuseppe, Daniele Andreis, Sara Bravaccini, et al.. (2017). Sorafenib for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 18(6). 621–630. 32 indexed citations
12.
Pietri, Elisabetta, Vincenza Conteduca, Daniele Andreis, et al.. (2016). Androgen receptor signaling pathways as a target for breast cancer treatment. Endocrine Related Cancer. 23(10). R485–R498. 83 indexed citations
13.
Rocca, Andrea, Lorenzo Cecconetto, Alessandro Passardi, et al.. (2016). A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.. Journal of Clinical Oncology. 34(15_suppl). 600–600. 2 indexed citations
14.
Giotta, Francesco, Giampiero Candeloro, Pietro Del Medico, et al.. (2016). Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes. The Oncologist. 21(11). 1298–1305. 9 indexed citations
15.
Rocca, Andrea, Alberto Farolfi, Roberta Maltoni, et al.. (2015). Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Research and Treatment. 152(1). 57–65. 17 indexed citations
16.
Rocca, Andrea, Daniele Andreis, Anna Fedeli, et al.. (2015). Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. Expert Opinion on Drug Metabolism & Toxicology. 11(10). 1647–1663. 11 indexed citations
17.
Tenti, Elena, et al.. (2015). Medication reconciliation in cancer day hospital.. Journal of Clinical Oncology. 33(15_suppl). e17748–e17748. 1 indexed citations
18.
19.
Farolfi, Alberto, Emanuela Scarpi, Alessio Schirone, et al.. (2014). Time to Initiation of Adjuvant Chemotherapy in Patients with Rapidly Proliferating Early Breast Cancer. Annals of Oncology. 25. iv89–iv89. 1 indexed citations
20.
Rocca, Andrea, Alberto Farolfi, Sara Bravaccini, Alessio Schirone, & Dino Amadori. (2013). Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. Expert Opinion on Pharmacotherapy. 15(3). 407–420. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kateřina Bouchalová Breakdown of academic impact, for papers by Sheau Wen Lok Breakdown of academic impact, for papers by Qiufan Zheng Breakdown of academic impact, for papers by Djamila Ouaret Breakdown of academic impact, for papers by LA Carey Breakdown of academic impact, for papers by Salo Ooft Breakdown of academic impact, for papers by Jutta Groos Breakdown of academic impact, for papers by Erica Stringer-Reasor Breakdown of academic impact, for papers by Xinghua Han Breakdown of academic impact, for papers by Sean E. Sissons
Rankless by CCL
2026